How India Exports Albendazole to the World

In the United States, Albendazole is approved for the treatment of various parasitic infections. The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for Albendazole, indicating a competitive generic market. Recent approvals include [specific approval dates and ANDA numbers, if available]. As of March 2026, there are no active FDA import alerts specifically targeting Albendazole from Indian manufacturers, suggesting compliance with U.S. regulatory standards. Given the presence of 628 active Indian exporters, it is imperative for each to adhere strictly to FDA regulations to maintain market access.

In the European Union, Albendazole requires marketing authorization from the European Medicines Agency (EMA) before it can be marketed. The EMA ensures that medicines meet EU standards for safety, efficacy, and quality. Similarly, in the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) oversees the approval process. Both agencies mandate compliance with Good Manufacturing Practice (GMP) requirements, which are critical for Indian exporters aiming to penetrate these markets. The significant export percentages to the Netherlands (9.2%), France (8.0%), and Denmark (7.3%) underscore the importance of adhering to these stringent regulatory standards.

Albendazole is included in the 24th edition of the WHO Model List of Essential Medicines, published in September 2025, highlighting its importance in addressing global health needs. The 11th Edition of The International Pharmacopoeia, published in March 2023, includes monographs for Albendazole, providing standardized quality specifications. Compliance with these standards is essential for manufacturers to ensure global acceptance and facilitate international trade.

In India, Albendazole is classified under Schedule H of the Drugs and Cosmetics Act, requiring a prescription for dispensing. The National Pharmaceutical Pricing Authority (NPPA) sets ceiling prices for essential medicines; however, the specific ceiling price for Albendazole as of March 2026 would need to be confirmed from the latest NPPA notifications. For exports, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC) to ensure compliance with national regulations and to monitor the quality of pharmaceutical exports.

Albendazole's primary patents have expired, leading to a robust generic market with multiple manufacturers producing the drug. This competitive landscape has contributed to the average FOB unit price of $2.84, as observed in the export data from 2022 to 2026.

In May 2025, the WHO Expert Committee on Selection and Use of Essential Medicines convened to update the Model List of Essential Medicines, reaffirming Albendazole's inclusion due to its critical role in treating parasitic infections. In September 2025, the WHO published the 24th edition of the Model List of Essential Medicines, which includes Albendazole, underscoring its continued importance in global health. In March 2023, the WHO released the 11th Edition of The International Pharmacopoeia, featuring updated monographs for Albendazole, providing standardized quality specifications for manufacturers. In April 2025, the WHO unveiled a global repository for National Essential Medicines Lists (nEMLs), facilitating access to information on essential medicines, including Albendazole, across different countries. In February 2025, the WHO highlighted the role of biosimilars in expanding access to essential biologic therapies, emphasizing the importance of quality-assured medicines like Albendazole in achieving universal health coverage.

These developments reflect the ongoing global commitment to ensuring the availability and quality of essential medicines like Albendazole, reinforcing the need for Indian exporters to maintain high standards to meet international regulatory requirements.

India's pharmaceutical industry, including the production of Albendazole, heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China. Approximately 60–70% of these critical components are sourced from China, creating a significant dependency. This reliance exposes the supply chain to potential disruptions stemming from geopolitical tensions, trade restrictions, or environmental regulations affecting Chinese manufacturing.

In response, the Indian government has implemented the Production Linked Incentive (PLI) scheme to bolster domestic manufacturing of critical KSMs, DIs, and APIs. As of September 2025, this initiative has led to the establishment of manufacturing capacities for 26 KSMs and APIs, resulting in cumulative sales of ₹2,315 crore and avoiding imports worth ₹1,807 crore. While these efforts are commendable, the transition to self-reliance is ongoing, and the industry remains vulnerable to external supply chain shocks in the interim.

Our proprietary trade data indicates that the top five exporters of Albendazole from India account for 39.4% of the total export value, with MEPRO PHARMACEUTICALS PRIVATE LIMITED leading at a 13.6% share. This concentration suggests a moderate risk, as disruptions affecting these key suppliers could impact global supply chains.

The PLI scheme aims to mitigate such risks by promoting diversification and enhancing domestic production capabilities. By September 2025, the scheme had attracted investments exceeding initial commitments, with ₹4,763.34 crore invested against a commitment of ₹4,329.95 crore over six years. This proactive approach is expected to reduce single-source dependencies and strengthen the resilience of the pharmaceutical supply chain.

Global shipping routes, including the Red Sea and the Strait of Hormuz, are susceptible to geopolitical tensions that can disrupt maritime transport. Such disruptions can delay shipments of raw materials and finished pharmaceutical products, affecting supply chains. Additionally, ongoing US-China trade tensions have led to uncertainties in the availability and pricing of APIs and KSMs sourced from China.

Regulatory bodies like the FDA and EMA have issued shortage alerts for various pharmaceuticals in recent years, underscoring the impact of supply chain vulnerabilities. For instance, the FDA's Drug Shortages database lists multiple instances where supply disruptions have led to critical drug shortages. These events highlight the need for robust risk management strategies to navigate geopolitical and logistical challenges.

• Diversify Supplier Base: Engage with multiple suppliers across different regions to reduce dependency on a single source for APIs and KSMs.

• Enhance Domestic Production: Leverage government initiatives like the PLI scheme to invest in local manufacturing capabilities for critical raw materials.

• Strengthen Inventory Management: Maintain strategic stockpiles of essential APIs and KSMs to buffer against potential supply disruptions.

• Monitor Geopolitical Developments: Establish a dedicated team to track international events that could impact supply chains and develop contingency plans accordingly.

• Collaborate with Regulatory Bodies: Work closely with agencies like the FDA and EMA to stay informed about potential shortages and compliance requirements.

RISK_LEVEL: MEDIUM